November 2012 | OncologyLive

5 Subtyping Questions for Matthew J.C. Ellis, MB BChir, PhD

December 04, 2012

For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.

New Data on Horizon in Several Key Areas

December 03, 2012

Although new therapies have revolutionized the management of certain hematologic malignancies during the past 15 years, clinical trials currently under way hold the potential to yield new targeted agents and better treatment strategies.

Taking a Look at Four Noteworthy Studies

November 28, 2012

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

Surgeon Offers Perspective on Need for GI Navigators

November 20, 2012

For Johns Hopkins' gastrointestinal cancer surgeon Mark D. Duncan, those who help his patients cope with their diagnosis and manage their often complex treatment and follow-up are critical members of the healthcare team.

Bevacizumab PFS Benefit Extends Across Cohorts in AURELIA Trial

November 20, 2012

An exploratory analysis of the phase III AURELIA trial demonstrated that adding bevacizumab (Avastin) to chemotherapy in patients with platinum-resistant ovarian cancer benefited patients across treatment cohorts.

Pomalidomide Meets Primary PFS Endpoint

November 20, 2012

A data safety monitoring board (DSMB) has found that a phase III study of pomalidomide, an oral immunomodulatory agent, met its primary endpoint by demonstrating a significant improvement in progression-free survival for patients with multiple myeloma (MM).

Vaccine Promotes Immune Response in Ovarian Cancer

November 19, 2012

Interim data from a phase II clinical study of the dendritic cell vaccine CVac in patients with epithelial ovarian cancer showed promising signs of improving PFS compared with the observational standard of care.